TVTX$27.82
$28.58
Chart
Performance
Key Stats
AI TVTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyTravere Therapeutics shows promising fundamental strength in its niche market with a strong commitment to rare disease treatments. However, recent performance shows volatility, and ongoing clinical trial success is crucial. Technical indicators are mixed, suggesting a wait-and-see approach for optimal entry points.
Thematic
Travere Therapeutics is positioned in the high-growth, high-impact rare disease therapeutics sector, with a focus on specific unmet medical needs. The company's pipeline addresses significant patient populations with limited treatment options.
Fundamental
Travere Therapeutics is in a growth phase with increasing revenues but currently operates at a net loss, typical for biopharma companies investing heavily in R&D. The balance sheet shows substantial debt, but also a significant amount of cash to fund operations. Valuation multiples are high, reflecting future growth expectations.
Technical
Travere Therapeutics' stock has experienced significant volatility over the past year. While it shows periods of strong upward momentum, it also faces resistance and has traded within a range. Technical indicators provide mixed signals, suggesting a cautious approach.
| Factor | Score |
|---|---|
| Rare Disease Therapeutics | 90 |
| Clinical Pipeline Progression | 85 |
| Orphan Drug Designation | 92 |
| Biopharmaceutical Innovation | 70 |
| Regulatory & Market Access | 65 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 15 |
| Growth | 70 |
| Balance Sheet Health | 30 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 65 |
| Moving Averages | 70 |
| Support & Resistance | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Trailing P/S Ratio
The trailing Price-to-Sales (P/S) ratio of 6.5 indicates investor confidence in the company's ability to generate revenue, which is crucial for a growth-oriented biopharmaceutical company.
Strong Short-Term Performance
The stock has shown positive performance over the last 5 days (0.82%), 1 month (5.42%), and 1 year (61.27%), suggesting recent positive investor sentiment and upward momentum.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses in all reported annual and quarterly periods (e.g., net income of -$321,545,000 in 2024, -$41,226,000 in 2025Q1), indicating a lack of profitability.
Negative P/E Ratio
The trailing Price-to-Earnings (P/E) ratio is negative (-9.1 TTM, -4.8 for 2024), which is typical for unprofitable companies but highlights the absence of current earnings to justify the valuation.
Calendar
July 2025
30
Next Earnings Date
H: $0.13
A: $-0.01
L: $-0.15
H: 114.40M
A: 99.96M
L: 77.76M
Profile
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Seasonals
Price Target
34.27 USD
The 39 analysts offering 1 year price forecasts for TVTX have a max estimate of 47.00 and a min estimate of 23.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor in IgA Nephropathy (IgAN) with an approved drug (Tarpeyo/Kinpeygo), directly addressing the same market as TVTX's FILSPARI.
Weight: 98
Direct competitor in IgA Nephropathy (IgAN) with a late-stage clinical program (atacicept) targeting the same disease area as TVTX's approved product.
Weight: 95
Direct competitor in Fabry Disease with an approved oral precision medicine (Galafold), a disease area where TVTX also has an approved treatment (FABRYZME).
Weight: 92
Major pharmaceutical company with a significant rare disease portfolio, including an approved enzyme replacement therapy (Fabrazyme) for Fabry Disease, directly competing with TVTX's FABRYZME.